Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Oral Venglustat in Healthy Volunteers - Peterschmitt, M. Judith; Crawford, Nigel P. S.; Gaemers, Sebastiaan J. M.; Ji, Allena J.; Sharma, Jyoti; Pham, Theresa T. (Clinical pharmacology in drug development, 2021)
Keywords: Administration, Oral; Adolescent; Adult; Carbamates - administration & dosage; Carbamates - adverse effects; Carbamates - pharmacokinetics; Cross-Over Studies; Disease; Double-Blind Method; Enzyme Inhibitors - adverse effects; Enzyme Inhibitors - pharmacokinetics; Enzyme Inhibitors - pharmacology; Female; Gangliosides - blood; globotriaosylceramide (GL‐3); glucosylceramide (GL‐1); glucosylceramide synthase (GCS) inhibition; Glucosylceramides - blood; glucosylsphingosine (lyso‐GL‐1); Glucosyltransferases - antagonists & inhibitors; Healthy Volunteers; Humans; Kidney diseases; Male; Middle Aged; monosialodihexosylganglioside (GM3); Original Manuscript; Pharmacodynamics; Pharmacokinetics; Quinuclidines - administration & dosage; Quinuclidines - adverse effects; Quinuclidines - pharmacokinetics; substrate reduction therapy; venglustat (GZ/SAR402671; Genz‐682452); Young Adult; glucosylceramide (GL-1); glucosylceramide synthase (GCS) inhibition; venglustat (GZ/SAR402671; Genz-682452); substrate reduction therapy; globotriaosylceramide (GL-3); glucosylsphingosine (lyso-GL-1); monosialodihexosylganglioside (GM3)